Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
Status:
Terminated
Trial end date:
2019-06-19
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can
cause fibrosis regression and reduce progression to cirrhosis and associated complications in
adults with NASH and bridging (F3) fibrosis.